Fintel reports that on December 2, 2024, Citigroup initiated coverage of Voyager Therapeutics (NasdaqGS:VYGR) with a Buy recommendation.
Analyst Price Forecast Suggests 156.07% Upside
As of November 21, 2024, the average one-year price target for Voyager Therapeutics is $17.57/share. The forecasts range from a low of $7.07 to a high of $31.50. The average price target represents an increase of 156.07% from its latest reported closing price of $6.86 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Voyager Therapeutics is 12MM, a decrease of 92.84%. The projected annual non-GAAP EPS is -1.81.
What is the Fund Sentiment?
There are 329 funds or institutions reporting positions in Voyager Therapeutics. This is an increase of 8 owner(s) or 2.49% in the last quarter. Average portfolio weight of all funds dedicated to VYGR is 0.04%, an increase of 29.89%. Total shares owned by institutions increased in the last three months by 1.23% to 39,738K shares. 
The put/call ratio of VYGR is 0.84, indicating a bullish outlook.
What are Other Shareholders Doing?
Armistice Capital holds 5,200K shares representing 9.52% ownership of the company. No change in the last quarter.
EcoR1 Capital holds 3,918K shares representing 7.17% ownership of the company. No change in the last quarter.
Farallon Capital Management holds 2,292K shares representing 4.20% ownership of the company. No change in the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 1,714K shares representing 3.14% ownership of the company. In its prior filing, the firm reported owning 1,628K shares , representing an increase of 5.02%. The firm decreased its portfolio allocation in VYGR by 26.87% over the last quarter.
IWM - iShares Russell 2000 ETF holds 1,219K shares representing 2.23% ownership of the company. In its prior filing, the firm reported owning 903K shares , representing an increase of 25.96%. The firm decreased its portfolio allocation in VYGR by 13.82% over the last quarter.
Voyager Therapeutics Background Information
(This description is provided by the company.)
Voyager Therapeutics is a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases. Voyager is committed to advancing the field of AAV gene therapy through innovation and investment in vector engineering and optimization, manufacturing, and dosing and delivery techniques. Voyager's wholly owned and partnered pipeline focuses on severe neurological diseases for which effective new therapies are needed, including Parkinson's disease, Huntington's disease, Friedreich's ataxia, and other severe neurological diseases.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
